Medizone International, Inc. Appoints Dr. Michael E. Shannon to Its Board of Directors

Thursday, August 21, 2008 General News
Email Print This Page Comment bookmark
Font : A-A+

SAN FRANCISCO, Aug. 21 Medizone International,Inc. (Pink Sheets: MZEI) announces the appointment of Michael E. Shannon,M.A., M.Sc., M.D. to its Board of Directors. Dr. Shannon received his medicaldegree from Queen's University in Canada, which included advanced training insurgery and sports medicine. He also holds post-graduate degrees inneurochemistry and physiology. He has been actively engaged in appliedmedical research within these areas for over 27 years. He served in theCanadian Forces for 31 years retiring at the rank of Commodore (BrigadierGeneral equivalent) as Deputy Surgeon General for Canada. During the firstGulf War, Dr. Shannon served as the senior medical liaison officer for all ofthe Canadian forces. In 1996 he assumed responsibilities within Health Canadafor re-organizing the Canadian blood system. Working with both the provincialand federal governments, he oversaw the development of a new corporate entitydedicated exclusively to the management of blood services in Canada. He wasthen appointed Director General for the Laboratory Centre for Disease Control,a position he held for three years. In December 2000, Dr. Shannon left theCanadian federal government to pursue a new career in industry. In thatcapacity he simultaneously directed a phase III clinical trial in Canada, theUnited States and Great Britain for an artificial blood substitute product.Following completion of that work he was asked to accept a special assignmentwith the Canadian Federal Government Auditor General's office. His assignmentwas to conduct a cost benefit analysis of all government sponsored pharmacareprograms and make recommendations directly to the Parliament of Canada. Hisassignment and presentation to Parliament on that project was completed inNovember 2004. Dr. Shannon recently worked on a special project assignment asSenior Medical Advisor to the Canadian Public Health Agency. His assignmentwas to review and help rebuild the Canadian Public Health Agency's EmergencyMedical Response Capacity. His work in that regard with the Canadiangovernment was completed the end of July this year.

Internationally respected for his expertise, Dr. Shannon has been activelyengaged in medical bio-oxidative (O3 based), research since 1987 and wasdirectly responsible for the first human clinical trial to have ever beenapproved in North America which examined the efficacy of O3 delivered viaautohemotherapy in the treatment of AIDS. He was also responsible for severalprimate studies utilizing O3 involving scientists from various departmentswithin the Canadian Federal Government, as well as senior investigators fromMedizone International and Cornell University.

Medizone's Chairman and CEO, Edwin Marshall commented; "On behalf of themembers of the board and all of the Company's shareholders, we welcome Dr.Shannon to our Board of Directors. The wisdom and expertise Dr. Shannonbrings to Medizone is unparalleled in the history of our company. I considerhim a remarkable man and feel honored to be able to refer to him as aprofessional associate. This appointment signals an immense step forward inthe reorganization of Medizone International.

Medizone International, Inc., is a research and development stage companyengaged in the development of patented and unpatented technologies andprotocols for O3 based bio-oxidative treatment of diseases caused by lipidenveloped viruses, including Acquired Immune Deficiency Syndrome (AIDS),Hepatitis B & C, and Herpes, the decontamination of blood, blood products andveterinarian serum products, and the treatment of external pathogenicconditions.

This Press Release contains certain forward looking statements thatinvolve substantial risks and uncertainties, including, but not limited to,the results of ongoing clinical studies, economic conditions, product andtechnology development, production efficiencies, product demand,

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store